{"success":true,"data":{"pressRelease":{"id":"163538","rtpr_id":"nBw7Bwqwwa-20261007","ticker":"GKOS","exchange":"NYSE","all_tickers":["GKOS"],"title":"Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus","author":"Business Wire","published_at":"2026-10-07T20:05:00.139Z","article_body":"Glaukos Announces Positive Three-Year Epioxa(®) Results Demonstrating Durable\nClinical Outcomes in Keratoconus\n\nThree-year data demonstrate sustained improvements in corneal shape,\nmeaningful visual acuity gains, and a favorable long-term safety profile\nfollowing a single treatment\n\nGlaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical\ntechnology company focused on novel therapies for the treatment of glaucoma,\ncorneal disorders, and retinal diseases, announced today positive topline\nresults from a long-term Phase 3 extension study (GLK-202-03) evaluating the\ndurability, visual outcomes, and safety of Epioxa(®), the company's\ngroundbreaking epi-on corneal cross-linking therapy for the treatment of\nkeratoconus, a sight-threatening corneal disease that remains significantly\nundiagnosed and undertreated. The extension study followed a cohort of\npatients for three years after cross-linking treatment in Epioxa’s second\nPhase 3 pivotal trial (GLK-202-02).\n\nThe long-term follow-up results demonstrated durable efficacy and a favorable\nlong-term safety profile through three years following a single Epioxa\ntreatment, with no additional intervention during the extension period.\nTreated eyes achieved a sustained 1.9 diopter (D) improvement in maximum\ncorneal curvature (Kmax) from baseline, reflecting meaningful long-term\ncorneal flattening and stabilization. Treated eyes also demonstrated\nclinically meaningful visual outcomes at year 3, with 29% and 20% of eyes\ngaining two or more and three or more lines of best-corrected visual acuity\nfrom baseline, respectively. The durability of these findings further supports\nEpioxa's potential to provide long-term disease stabilization following a\nsingle treatment. In addition, treated eyes maintained a favorable long-term\nsafety profile through three years, with no serious adverse events,\ntreatment-related adverse events, or discontinuations due to adverse events.\n\n\"These long-term results further reinforce the potential of Epioxa to provide\ndurable clinical benefits for patients living with keratoconus,\" said Thomas\nBurns, chairman and chief executive officer of Glaukos. \"The sustained\nimprovements in corneal shape and visual acuity, coupled with an excellent\nlong-term safety profile, reinforce our view that Epioxa represents a\ntransformative treatment advancement for keratoconus patients.\"\n\nGLK-202-03 is a long-term extension study designed to evaluate the safety,\ndurability, and clinical outcomes of a cohort of patients who completed the\nPhase 3 GLK-202-02 trial and received corneal cross-linking treatment during\nthe initial study period. Patients were followed for up to 3 years after\ntreatment, with efficacy assessments focused on changes in corneal curvature\nand visual acuity. A total of 38 study eyes from 35 subjects participated, and\n92% of eyes completed the year 3 visit.\n\nEpioxa represents a transformative innovation in keratoconus care, offering an\nincision-free alternative to traditional corneal cross-linking procedures as\nit does not require the removal of the corneal epithelium, the outermost layer\nof the front of the eye. This novel, oxygen-supplemented topical therapeutic,\nbioactivated by pulsed UV light, is designed to significantly reduce the pain\nassociated with removal of the epithelium, streamline the procedure, and\nminimize recovery, all while delivering robust clinically meaningful and\ndurable outcomes and exceptional value to patients, providers, and the\nhealthcare system.\n\nFor more information about Epioxa HD / Epioxa and Full Prescribing\nInformation, please visit www.Epioxa.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.epioxa.com%2F&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.Epioxa.com&index=1&md5=b9e565eb166843edcdf8b0ae23f1f2e7)\n.\n\nAbout Glaukos\n\nGlaukos (www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=2&md5=f46ac862e082ae27509376f795e79534)\n) is an ophthalmic pharmaceutical and medical technology company focused on\ndeveloping and commercializing novel therapies for the treatment of glaucoma,\ncorneal disorders, and retinal diseases. Glaukos first developed\nMicro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional\nglaucoma treatment paradigm, launching its first MIGS device commercially in\n2012. In 2024, Glaukos commenced commercial launch activities for iDose(®)\nTR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical\ndesigned to deliver 24/7 glaucoma drug therapy inside the eye for extended\nperiods of time. Glaukos also markets the only FDA-approved corneal\ncross-linking therapy utilizing a proprietary bio-activated pharmaceutical for\nthe treatment of keratoconus, a rare corneal disorder. Glaukos continues to\nsuccessfully develop and advance a robust pipeline of novel, dropless platform\ntechnologies designed to meaningfully advance the standard of care and improve\noutcomes for patients suffering from chronic eye diseases.\n\nAbout Epioxa HD / Epioxa\n\nIndication: EPIOXA HD (riboflavin 5’-phosphate ophthalmic solution) 0.239%\nand EPIOXA (riboflavin 5’-phosphate ophthalmic solution) 0.177% are\nphotoenhancers indicated for use in epithelium-on corneal collagen\ncross-linking for the treatment of keratoconus in adults and pediatric\npatients aged 13 years and older, in conjunction with the O(2)n(®) System and\nthe Boost Goggles(®).\n\nDosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic\nuse. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied\nin single-dose syringes. Discard opened syringes after use. EPIOXA HD and\nEPIOXA are for use with the O(2)n System and Boost Goggles only. Refer to the\nO(2)n System Operator’s Manual and Boost Goggles User Guide for device\ninstructions.\n\nContraindications: EPIOXA HD and EPIOXA are contraindicated in patients with\nknown hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA\nHD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated\nin aphakic and pseudophakic patients without a UV-blocking intraocular lens.\n\nWarnings and Precautions: Corneal collagen cross-linking should be used with\ncaution in patients with a history of herpetic keratitis due to the potential\nfor reactivation of herpes keratitis.\n\nAdverse Reactions: The most common adverse reaction was conjunctival\nhyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes\nincluded: corneal opacity (haze), photophobia, punctate keratitis, eye pain,\neye irritation, increased lacrimation, corneal epithelium defect, eyelid\noedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber\nflare.\n\nFor more information, visit www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=3&md5=1072f65f7d9767a85ffffd71dfc37af0)\n.\n\nForward-Looking Statements\n\nAll statements other than statements of historical facts included in this\npress release that address activities, events or developments that we expect,\nbelieve or anticipate will or may occur in the future are forward-looking\nstatements. Although we believe that we have a reasonable basis for\nforward-looking statements contained herein, we caution you that they are\nbased on current expectations about future events affecting us and are subject\nto risks, uncertainties and factors relating to our operations and business\nenvironment, all of which are difficult to predict and many of which are\nbeyond our control, that may cause our actual results to differ materially\nfrom those expressed or implied by forward-looking statements in this press\nrelease. These potential risks and uncertainties include, without limitation,\nthe timing and extent to which we obtain regulatory approval for\ninvestigational products, our ability to successfully commercialize such\nproducts, the ability to obtain and maintain adequate financial coverage and\nreimbursement for our products, and the continued efficacy and safety profile\nof our products. These and other risks, uncertainties and factors related to\nGlaukos, and our business are described in detail under the caption “Risk\nFactors” and elsewhere in our Quarterly Report on Form 10-Q for the quarter\nended June 30, 2026, which was filed with the SEC on July 29, 2026. Our\nfilings with the SEC are available in the Investor Section of our website at\nwww.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=4&md5=92ebd0087b3b3a8beff867adfdda35bd)\nor at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.sec.gov&index=5&md5=b3d5cfecf859d0337f9585fb6a8b83b0)\n. In addition, information about the risks and benefits of our products is\navailable on our website at www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=6&md5=f5d65f5450b9173b2c868122ea5db5aa)\n. All forward-looking statements included in this press release are expressly\nqualified in their entirety by the foregoing cautionary statements. You are\ncautioned not to place undue reliance on the forward-looking statements in\nthis press release, which speak only as of the date hereof. We do not\nundertake any obligation to update, amend or clarify these forward-looking\nstatements whether as a result of new information, future events or otherwise,\nexcept as may be required under applicable securities law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007149511/en/\n(https://www.businesswire.com/news/home/20261007149511/en/)\n\nMedia Contact:\n\nMichele Gray\n\n(917) 449-9250\n\nmichele@mgraycommunications.com \n(mailto:michele@mgraycommunications.com) \n\n\nInvestor Contact:\n\nChris Lewis\n\nVice President, Investor Relations & Corporate Affairs\n\nclewis@glaukos.com (mailto:clewis@glaukos.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7Bwqwwa-20261007","title":"Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus","author":"Business Wire","ticker":"GKOS","created":"2026-10-07T20:05:00.139Z","tickers":["GKOS"],"exchange":"NYSE","article_body":"Glaukos Announces Positive Three-Year Epioxa(®) Results Demonstrating Durable\nClinical Outcomes in Keratoconus\n\nThree-year data demonstrate sustained improvements in corneal shape,\nmeaningful visual acuity gains, and a favorable long-term safety profile\nfollowing a single treatment\n\nGlaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical\ntechnology company focused on novel therapies for the treatment of glaucoma,\ncorneal disorders, and retinal diseases, announced today positive topline\nresults from a long-term Phase 3 extension study (GLK-202-03) evaluating the\ndurability, visual outcomes, and safety of Epioxa(®), the company's\ngroundbreaking epi-on corneal cross-linking therapy for the treatment of\nkeratoconus, a sight-threatening corneal disease that remains significantly\nundiagnosed and undertreated. The extension study followed a cohort of\npatients for three years after cross-linking treatment in Epioxa’s second\nPhase 3 pivotal trial (GLK-202-02).\n\nThe long-term follow-up results demonstrated durable efficacy and a favorable\nlong-term safety profile through three years following a single Epioxa\ntreatment, with no additional intervention during the extension period.\nTreated eyes achieved a sustained 1.9 diopter (D) improvement in maximum\ncorneal curvature (Kmax) from baseline, reflecting meaningful long-term\ncorneal flattening and stabilization. Treated eyes also demonstrated\nclinically meaningful visual outcomes at year 3, with 29% and 20% of eyes\ngaining two or more and three or more lines of best-corrected visual acuity\nfrom baseline, respectively. The durability of these findings further supports\nEpioxa's potential to provide long-term disease stabilization following a\nsingle treatment. In addition, treated eyes maintained a favorable long-term\nsafety profile through three years, with no serious adverse events,\ntreatment-related adverse events, or discontinuations due to adverse events.\n\n\"These long-term results further reinforce the potential of Epioxa to provide\ndurable clinical benefits for patients living with keratoconus,\" said Thomas\nBurns, chairman and chief executive officer of Glaukos. \"The sustained\nimprovements in corneal shape and visual acuity, coupled with an excellent\nlong-term safety profile, reinforce our view that Epioxa represents a\ntransformative treatment advancement for keratoconus patients.\"\n\nGLK-202-03 is a long-term extension study designed to evaluate the safety,\ndurability, and clinical outcomes of a cohort of patients who completed the\nPhase 3 GLK-202-02 trial and received corneal cross-linking treatment during\nthe initial study period. Patients were followed for up to 3 years after\ntreatment, with efficacy assessments focused on changes in corneal curvature\nand visual acuity. A total of 38 study eyes from 35 subjects participated, and\n92% of eyes completed the year 3 visit.\n\nEpioxa represents a transformative innovation in keratoconus care, offering an\nincision-free alternative to traditional corneal cross-linking procedures as\nit does not require the removal of the corneal epithelium, the outermost layer\nof the front of the eye. This novel, oxygen-supplemented topical therapeutic,\nbioactivated by pulsed UV light, is designed to significantly reduce the pain\nassociated with removal of the epithelium, streamline the procedure, and\nminimize recovery, all while delivering robust clinically meaningful and\ndurable outcomes and exceptional value to patients, providers, and the\nhealthcare system.\n\nFor more information about Epioxa HD / Epioxa and Full Prescribing\nInformation, please visit www.Epioxa.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.epioxa.com%2F&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.Epioxa.com&index=1&md5=b9e565eb166843edcdf8b0ae23f1f2e7)\n.\n\nAbout Glaukos\n\nGlaukos (www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=2&md5=f46ac862e082ae27509376f795e79534)\n) is an ophthalmic pharmaceutical and medical technology company focused on\ndeveloping and commercializing novel therapies for the treatment of glaucoma,\ncorneal disorders, and retinal diseases. Glaukos first developed\nMicro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional\nglaucoma treatment paradigm, launching its first MIGS device commercially in\n2012. In 2024, Glaukos commenced commercial launch activities for iDose(®)\nTR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical\ndesigned to deliver 24/7 glaucoma drug therapy inside the eye for extended\nperiods of time. Glaukos also markets the only FDA-approved corneal\ncross-linking therapy utilizing a proprietary bio-activated pharmaceutical for\nthe treatment of keratoconus, a rare corneal disorder. Glaukos continues to\nsuccessfully develop and advance a robust pipeline of novel, dropless platform\ntechnologies designed to meaningfully advance the standard of care and improve\noutcomes for patients suffering from chronic eye diseases.\n\nAbout Epioxa HD / Epioxa\n\nIndication: EPIOXA HD (riboflavin 5’-phosphate ophthalmic solution) 0.239%\nand EPIOXA (riboflavin 5’-phosphate ophthalmic solution) 0.177% are\nphotoenhancers indicated for use in epithelium-on corneal collagen\ncross-linking for the treatment of keratoconus in adults and pediatric\npatients aged 13 years and older, in conjunction with the O(2)n(®) System and\nthe Boost Goggles(®).\n\nDosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic\nuse. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied\nin single-dose syringes. Discard opened syringes after use. EPIOXA HD and\nEPIOXA are for use with the O(2)n System and Boost Goggles only. Refer to the\nO(2)n System Operator’s Manual and Boost Goggles User Guide for device\ninstructions.\n\nContraindications: EPIOXA HD and EPIOXA are contraindicated in patients with\nknown hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA\nHD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated\nin aphakic and pseudophakic patients without a UV-blocking intraocular lens.\n\nWarnings and Precautions: Corneal collagen cross-linking should be used with\ncaution in patients with a history of herpetic keratitis due to the potential\nfor reactivation of herpes keratitis.\n\nAdverse Reactions: The most common adverse reaction was conjunctival\nhyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes\nincluded: corneal opacity (haze), photophobia, punctate keratitis, eye pain,\neye irritation, increased lacrimation, corneal epithelium defect, eyelid\noedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber\nflare.\n\nFor more information, visit www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=3&md5=1072f65f7d9767a85ffffd71dfc37af0)\n.\n\nForward-Looking Statements\n\nAll statements other than statements of historical facts included in this\npress release that address activities, events or developments that we expect,\nbelieve or anticipate will or may occur in the future are forward-looking\nstatements. Although we believe that we have a reasonable basis for\nforward-looking statements contained herein, we caution you that they are\nbased on current expectations about future events affecting us and are subject\nto risks, uncertainties and factors relating to our operations and business\nenvironment, all of which are difficult to predict and many of which are\nbeyond our control, that may cause our actual results to differ materially\nfrom those expressed or implied by forward-looking statements in this press\nrelease. These potential risks and uncertainties include, without limitation,\nthe timing and extent to which we obtain regulatory approval for\ninvestigational products, our ability to successfully commercialize such\nproducts, the ability to obtain and maintain adequate financial coverage and\nreimbursement for our products, and the continued efficacy and safety profile\nof our products. These and other risks, uncertainties and factors related to\nGlaukos, and our business are described in detail under the caption “Risk\nFactors” and elsewhere in our Quarterly Report on Form 10-Q for the quarter\nended June 30, 2026, which was filed with the SEC on July 29, 2026. Our\nfilings with the SEC are available in the Investor Section of our website at\nwww.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=4&md5=92ebd0087b3b3a8beff867adfdda35bd)\nor at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.sec.gov&index=5&md5=b3d5cfecf859d0337f9585fb6a8b83b0)\n. In addition, information about the risks and benefits of our products is\navailable on our website at www.glaukos.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.glaukos.com&esheet=54617459&newsitemid=20261007149511&lan=en-US&anchor=www.glaukos.com&index=6&md5=f5d65f5450b9173b2c868122ea5db5aa)\n. All forward-looking statements included in this press release are expressly\nqualified in their entirety by the foregoing cautionary statements. You are\ncautioned not to place undue reliance on the forward-looking statements in\nthis press release, which speak only as of the date hereof. We do not\nundertake any obligation to update, amend or clarify these forward-looking\nstatements whether as a result of new information, future events or otherwise,\nexcept as may be required under applicable securities law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007149511/en/\n(https://www.businesswire.com/news/home/20261007149511/en/)\n\nMedia Contact:\n\nMichele Gray\n\n(917) 449-9250\n\nmichele@mgraycommunications.com \n(mailto:michele@mgraycommunications.com) \n\n\nInvestor Contact:\n\nChris Lewis\n\nVice President, Investor Relations & Corporate Affairs\n\nclewis@glaukos.com (mailto:clewis@glaukos.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-07T20:05:00.182885884Z","server_sent_at_ms":1791403500182},"received_at":"2026-10-07T20:05:00.317Z","source_url":"https://www.businesswire.com/news/home/20261007149511/en/"},"analysis":{"id":"152001","press_release_id":"163538","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Glaukos reported positive three-year results from its Phase 3 extension study (GLK-202-03) of Epioxa, its epi-on corneal cross-linking therapy for keratoconus, showing durable efficacy after a single treatment.\n\nTreated eyes sustained a 1.9 diopter improvement in maximum corneal curvature, with 29% and 20% of eyes gaining two or more and three or more lines of best-corrected visual acuity, respectively, and no serious adverse events through three years.\n\nThe durability data support Epioxa's long-term disease-stabilization profile and may bolster commercial adoption and payer coverage for the commercially launched therapy.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Three-year durability data with clean safety de-risks Epioxa's commercial trajectory in keratoconus."},"keyFigures":{"drugName":"Epioxa (riboflavin 5'-phosphate ophthalmic solution)","phaseOfTrial":"Phase 3","customDimensions":{"subjects":35,"study_eyes":38,"kmax_improvement_diopters":1.9,"year3_visit_completion_pct":"92%","eyes_gaining_2plus_lines_bcva_pct":"29%","eyes_gaining_3plus_lines_bcva_pct":"20%"}},"quotedText":"These long-term results further reinforce the potential of Epioxa to provide durable clinical benefits for patients living with keratoconus","namedEntities":{"people":[{"name":"Thomas Burns","role":"Chairman and CEO of Glaukos"},{"name":"Michele Gray","role":"Media contact"},{"name":"Chris Lewis","role":"Vice President, Investor Relations & Corporate Affairs"}],"products":["Epioxa","Epioxa HD","iDose TR","O(2)n System","Boost Goggles"],"companies":[{"name":"Glaukos Corporation","ticker":"GKOS","relationship":"filer/issuer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive three-year extension data for a commercially launched FDA-approved product (Epioxa) supports durability claims, reimbursement, and adoption, but is not a binary regulatory or approval event."},"tickerRelevance":{"others":[],"primary":"GKOS"},"globalImportance":35,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","binaryEvent":false,"eventGravity":"positive long-term extension data for approved product","commercialImpact":"supports adoption and reimbursement"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Glaukos reported positive three-year results from its Phase 3 extension study (GLK-202-03) of Epioxa, its epi-on corneal cross-linking therapy for keratoconus, showing durable efficacy after a single treatment.\n\nTreated eyes sustained a 1.9 diopter improvement in maximum corneal curvature, with 29% and 20% of eyes gaining two or more and three or more lines of best-corrected visual acuity, respectively, and no serious adverse events through three years.\n\nThe durability data support Epioxa's long-term disease-stabilization profile and may bolster commercial adoption and payer coverage for the commercially launched therapy.","key_figures":{"drugName":"Epioxa (riboflavin 5'-phosphate ophthalmic solution)","phaseOfTrial":"Phase 3","customDimensions":{"subjects":35,"study_eyes":38,"kmax_improvement_diopters":1.9,"year3_visit_completion_pct":"92%","eyes_gaining_2plus_lines_bcva_pct":"29%","eyes_gaining_3plus_lines_bcva_pct":"20%"}},"named_entities":{"people":[{"name":"Thomas Burns","role":"Chairman and CEO of Glaukos"},{"name":"Michele Gray","role":"Media contact"},{"name":"Chris Lewis","role":"Vice President, Investor Relations & Corporate Affairs"}],"products":["Epioxa","Epioxa HD","iDose TR","O(2)n System","Boost Goggles"],"companies":[{"name":"Glaukos Corporation","ticker":"GKOS","relationship":"filer/issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T20:05:05.860Z","global_importance":35,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","binaryEvent":false,"eventGravity":"positive long-term extension data for approved product","commercialImpact":"supports adoption and reimbursement"}},"durationMs":5499,"modelName":"glm-5.3-flashx"}}